Abstract
Racial differences in serum prostate specific antigen (PSA) values in men with and without prostate cancer have been observed but have yet to be explained. We aimed to determine if ethnic variations in the rate of metabolism of PSA could explain the different levels of PSA found in African-American and Caucasian men. In a prospective fashion, patients diagnosed with biopsy-proven clinically localized adenocarcinoma of the prostate and scheduled for radical prostatectomy were selected for the study. Eleven patients (six Caucasian, five African-American) were enrolled in the study. All patients demonstrated normal liver and renal function. Sera for total PSA were obtained at the following time intervals: preoperative (within 3 months of operation), time 0 (at time of prostate removal), 1, 4, 8, 24, 48, 72, 168 and 336 h after removal of the prostate. A log–linear regression model was then used to determine the metabolic clearance rate and half-life of serum total PSA. There were no statistically significant differences between Caucasian and African-American patients with regard to age, PSA prior to surgery, prostate weight, Gleason sum and PSA half-life. The metabolic clearance of total PSA followed first order kinetics. When comparing serum PSA levels expressed as a fraction of the baseline PSA, Caucasian and African-American patients demonstrated similar rates of metabolism. This study found similar rates of elimination of serum total PSA between African-Americans and Caucasians. These findings suggest that the rate of metabolism of PSA is similar for these groups. Further studies are needed to explain racial differences of serum PSA in patients with and without prostate cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Powell IJ . Prostate cancer in the African-American: is this a different disease? Semin Urol Oncol 1998 16: 221–226
Freedland SJ et al. Clinical characteristics in black and white men with prostate cancer in an equal access medical center Urology 2000 55: 387–390
Moul JW et al. Racial differences in tumor volume and prostate specific antigen among radical prostatectomy patients J Urol 1999 162: 394–397
Moul JW et al. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men JAMA 1995 274: 1277–1281
Morgan TO et al. Age-specific reference ranges for prostate-specific antigen in black men New Engl J Med 1996 335: 304–310
Pettaway CA et al. Prostate specific antigen and pathological features of prostate cancer in black and white patients: a comparative study based on radical prostatectomy specimens J Urol 1998 160: 437–442
Polascik TJ, Oesterling JE, Partin AW . Prostate specific antigen: a decade of discovery—what we have learned and where we are going J Urol 1999 162: 293–306
Stamey TA et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate New Engl J Med 1987 317: 909–916
Oesterling JE et al. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy J Urol 1988 139: 766–772
Partin AW et al. Clearance rate of serum-free and total PSA following radical retropubic prostatectomy Prostate 1996 7: (Suppl) 35–39
Bjork T et al. Rapid exponential elimination of free prostate-specific antigen contrasts the slow, capacity-limited elimination of PSA complexed to alpha 1-antichymotrypsin from serum Urology 1998 51: 57–62
Stephan C et al. ACT-PSA and complexed PSA elimination kinetics in serum after radical retropubic prostatectomy: proof of new complex forming of PSA after release into circulation Urology 2000 55: 560–563
Ravery V, Meulemans A, Boccon-Gibod L . Clearance of free and total serum PSA after prostatic surgery Eur Urol 1998 33: 251–254
Agha AH et al. Prostate specific antigen is metabolized in the liver J Urol 1996 155: 1332–1335
Kilic S et al. Determination of the site of metabolism of total, free, and complexed prostate-specific antigen Urology 1998 52: 470–473
Birkenmeier G, Struck F, Gebhardt R . Clearance mechanism of prostate specific antigen and its complexes with alpha2-macroglobulin and alpha1-antichymotrypsin J Urol 1999 162: 897–901
Ross RK et al. 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males Lancet 1992 339: 887–889
Vijayakumar S et al. Results of a study to correlate serum prostate specific antigen and reproductive hormone levels in patients with localized prostate cancer J Natl Med Assoc 1995 87: 813–819
Irvine RA et al. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer Cancer Res 1995 55: 1937–1940
Moul JW et al. Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting J Urol 1996 155: 1667–1673
Powell IJ et al. The predictive value of race as a clinical prognostic factor among patients with clinically localized prostate cancer: a multivariate analysis of positive surgical margins Urology 1997 49: 726–731
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lotan, Y., Roehrborn, C. Clearance rates of total prostate specific antigen (PSA) after radical prostatectomy in African-Americans and Caucasians. Prostate Cancer Prostatic Dis 5, 111–114 (2002). https://doi.org/10.1038/sj.pcan.4500567
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.pcan.4500567
Keywords
This article is cited by
-
Tumorlokalisaties op PSMA-PET/CT bij patiënten met een persisterend meetbaar PSA na een radicale prostatectomie
Tijdschrift voor Urologie (2021)
-
Prediction of biochemical failure using prostate-specific antigen half-life in patients with adverse pathologic features after radical prostatectomy
World Journal of Urology (2019)